Placental microbial–metabolite profiles and inflammatory mechanisms associated with preterm birth by Parris, K.M. et al.
This is a repository copy of Placental microbial–metabolite profiles and inflammatory 
mechanisms associated with preterm birth.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/164688/
Version: Accepted Version
Article:
Parris, K.M. orcid.org/0000-0002-1382-5146, Amabebe, E. 
orcid.org/0000-0002-3924-5270, Cohen, M.C. et al. (1 more author) (2020) Placental 
microbial–metabolite profiles and inflammatory mechanisms associated with preterm birth. 
Journal of Clinical Pathology. ISSN 0021-9746 
https://doi.org/10.1136/jclinpath-2020-206536
This article has been accepted for publication in the Journal of Clinical Pathology, 2020 
following peer review, and the Version of Record can be accessed online at 
http://dx.doi.org/10.1136/jclinpath-2020-206536 © Authors (or their employer(s), 2020. 
Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs
and other images or illustrative material included where a another copyright owner is 
identified) is permitted strictly pursuant to the terms of the Creative Commons 
Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) 
https://creativecommons.org/licenses/by-nc/4.0/
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
Placental Microbial-Metabolite Profiles and Inflammatory Mechanisms Associated with 
Preterm Birth 
 
Kerry M. Parris,1+ Emmanuel Amabebe,1+ Marta C. Cohen, 1,2 Dilly O. Anumba1* 
1Department of Oncology and Metabolism, University of Sheffield, UK; 2Department of 
+LVWRSDWKRORJ\6KHIILHOG&KLOGUHQ¶V1+6)RXQGDWLRQ7UXVW8. 
 
+Joint First author 
*Corresponding author: 
Prof. Dilly O. Anumba MD, Department of Oncology and Metabolism, University of 
Sheffield, 4th Floor, Jessop Wing, Tree Root Walk, Sheffield S10 2SF, UK. +44 114 
2159707/2268148, d.o.c.anumba@sheffield.ac.uk  
 
Abstract 
 
There is growing emphasis on the potential significance of the placental microbiome and 
microbiome-metabolite interactions in immune responses and subsequent pregnancy 
outcome, especially in relation to preterm birth (PTB). This review discusses in detail the 
pathomechanisms of placental inflammatory responses and the resultant maternal-fetal 
allograft rejection in both microbial-induced and sterile conditions. It also highlights some 
potential placental-associated predictive markers of PTB for future investigation. The 
existence of a placental microbiome remains debatable. Therefore, an overview of our current 
understanding of the state and role of the placental microbiome (if it exists) and metabolome 
in human pregnancy is also provided. We critical evaluate the evidence for a placental 
microbiome, discuss its functional capacity through the elaborated metabolic products and 
also describe the consequent and more established feto-maternal inflammatory responses that 
stimulate the pathway to preterm premature rupture of membranes (PPROM), preterm labour 
(PTL) and spontaneous PTB.  
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Introduction 
This review provides an overview of our current understanding of the state and role of the 
not-yet proven placental microbiome and metabolome in human pregnancy. The human 
microbiome has existed as a complex, symbiotic ecosystem of microorganisms inhabiting 
human mucosal tissues and skin, yet its importance in health and disease has only been 
reported in recent years.(1) Growing evidence suggests a vital role for the human microbiome 
in immunity, metabolism and cancer but clarity remains required regarding whether 
microbiome dysregulation is the cause or consequence of these processes and conditions.(2-
5) Dysbiosis of the gut microbiome has been implicated in influencing tumorigenesis and 
cancer progression in gastrointestinal and systemic cancers (6) as well as in the development 
of polycystic ovary syndrome (PCOS), (7) Type 2 Diabetes (T2D) (8) and even mental health 
disorders such as anxiety and depression.(9) Research suggests a possible contribution from a 
deranged maternal gut microbiota in the development of atopy, the genetic tendency to 
develop allergic diseases such as rhinitis and asthma and autoimmune phenotypes in the 
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neonate(4), along with an increased risk of necrotising enterocolitis and sepsis.(10) 
Furthermore, emerging evidence of the interactions between placental and fetal gut and lung 
microbiomes highlights that dysregulation of these fetal microbiomes related to placental 
dysbiosis may influence short- and long-term neonatal complications such as 
bronchopulmonary dysplasia and necrotising enterocolitis amongst other morbidities.(10) 
Nonetheless, whether the maternal gut microbiota, and the subsequent impact on metabolic, 
hormonal and immunological factors during gestation, exerts any influence on the pregnancy 
itself remains unclear.(11)  
However, there is consensus on the role of the vaginal microbiome in health with a 
dominance of protective Lactobacillus species, which make up >70% of resident bacteria, 
found in the vagina of healthy, reproductive-age women.(11-14) Lowered disease risk and 
increased protection from opportunistic pathogens is considered to be the benefits of this 
dominance and the low pH of 4.5 observed in humans. Additionally, decreased relative 
abundance of Lactobacillus species in the vagina is strongly linked to bacterial vaginosis 
(BV) resulting in increased anaerobic bacterial respiration, pH valXHV  DQG LQFUHDVHG
risks of infertility, maternal infection (particularly sexually transmitted infections, STI), 
preterm premature rupture of membranes (PPROM) and preterm labour (PTL) through 
microbial ascent to the uterus.(12-15)  
The two-part Human Microbiome Project (HMP), spanning almost fifteen years, has sought 
to answer questions surrounding the uniqueness of the microbiome between humans and 
throughout different life stages, as well as how diversity contributes to function and 
dysfunction.(15, 16) The first part of the HMP revealed a microbiome distinctly different 
within each LQGLYLGXDO¶V niche iQ DGGLWLRQ WR D µSHUVRQDOLVHG¶ PLFURELRPH ZLWK GLVFUHWH
variants. The second part determined how changes to the host-microbiome interactions affect 
the stressors for three conditions - prediabetes, inflammatory bowel diseases and pregnancy 
including preterm birth (PTB). Lactobacillus dominance of the vaginal microbiome 
positively correlated to term birth$µVLJQDWXUH¶PLFURELRPHZDVGHVFULEHGIRUa high risk of 
PTB. However, pregnancy-related microbiomes for other tissues such as the placenta, uterus, 
breast milk or blood were not explored.(15) 
Despite this apparent oversight, evidence showed support for the translocation of maternal 
gut bacteria to breast milk and other extra-intestinal sites during pregnancy.(4) They also 
showed that the maternal gut microbiome exerts an influence on neonatal immunity most 
notably through colonisation of the neonatal gut during vaginal delivery.(4, 17, 18) 
Contrastingly, reports of hematogenous and in utero transmission of bacteria to identifiable 
placental and amniotic fluid microbiomes challenge the decades-ROG µVWHULOH ZRPE¶
paradigm.(19-23)  
 
Given the above raging controversy, this review discusses in detail the pathomechanism of 
placental inflammatory responses and the plausibly resultant maternal-fetal allograft rejection 
in both microbial-induced and sterile conditions. We also highlight some potential placental-
associated predictive markers of PTB for future investigation. The evidence for and against a 
placental microbiome is described and how this may interact with the placental metabolome 
during human pregnancy is also provided in the context of the more established feto-maternal 
3 
 
inflammatory responses that stimulate the pathway to preterm premature rupture of 
membranes (PPROM), preterm labour (PTL) and spontaneous PTB.  
  
Placental inflammatory response 
Histologic Features 
Spontaneous preterm birth (sPTB) is often associated with ascending intrauterine infection 
that triggers both maternal and fetal inflammatory responses, collectively referred to as the 
placental inflammatory response (PIR). Placental inflammatory response is associated with 
poor neonatal outcomes including low birth weight, sepsis, intraventricular haemorrhage, 
cerebral palsy, bronchopulmonary dysplasia, and neonatal mortality.(24, 25) The 
inflammatory responses of the placenta reflect the maternal and fetal inflammatory responses. 
PIR begins as a maternal inflammatory response with subsequent fetal inflammatory 
responses elicited if acute chorioamnionitis persists and increases in severity (24).  
 
The inflammatory response of the placenta that extends into the chorion, amnion or decidua 
is referred to as maternal inflammatory response. The hallmark of this response is histologic 
chorioamnionitis (HCA). On the other hand, inflammation that infiltrates the chorionic plate, 
umbilical cord (funisitis), and fetal blood vessels (vasculitis) is regarded as fetal 
inflammatory response (FIR), which is defined clinically as a fetal cord blood plasma IL-6 
concentration >11 pg/ml (24), and frequently associated with microbial invasion of the 
amniotic cavity.(24, 26)  
 
7KH IHWXV¶ FDSDFLW\ WR UHVSRQG WR EDFWHULDO FRORQLVDWLRQ GHYHORSV DIWHU  ± 21 ZHHN¶V
gestation and manifests as inflammation of the umbilical cord (funisitis). This fetal response 
begins in the umbilical vein (phlebitis) before progressing to one or both umbilical arteries 
DUWHULWLV DQG LQWR WKH :KDUWRQ¶V MHOO\ ZLWK WKLV SURJUHVVion being a good pathologic 
indicator of the stage and severity of the fetal inflammatory response.(27, 28) Some 
researchers regard both funisitis and chorioamnionitis as hallmarks of fetal inflammatory 
response syndrome (FIRS), however, the fetal inflammatory response indicates an increased 
severity and advancement of acute chorioamnionitis.(26, 29) Both maternal and fetal 
inflammatory responses are associated with PPROM but FIR in the placenta is usually more 
severe than MIR and more frequently associated with poor neonatal outcome.(25, 30) 
Preterm parturition is usually associated with HCA and infants born in such situation are at 
greater risk of sepsis and poor neurological, cardiorespiratory, gastrointestinal (including 
necrotising enterocolitis)  and renal outcomes.(24, 25, 31, 32) 
 
There is often chorioamnionitis (inflammation in the chorion and amnion) at placental 
examination with associated high concentration of cytokines in the amniotic fluid.(33) 
However, signs of intra-amniotic inflammation have been observed without elevated 
amniotic fluid cytokine levels.(33) Early detection has resulted in the identification of several 
inflammatory markers associated with PIR. 
 
Spontaneous PTB between 24-32 weeks are less common (<2% of all births) than late 
preterm births but are associated with greater risk of morbidity and mortality and evidence of 
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intrauterine infection and/or inflammation.(34) Histologic chorioamnionitis (HCA) is defined 
by inflammation of the chorion, amnion and placenta.(31) It is a frequent observation (~70%) 
in PTBs between 20-24 weeks gestation, but rare (16%) in deliveries after 34 weeks.(26) 
HCA is observed in 10% of term births, 30% of PTL with intact membranes and 50% of 
PPROM, with highest frequency of 80±90% in miscarriages at 20-24 weeks.(35) Despite the 
classic observation of HCA and high amniotic fluid concentrations of chemocytokines or 
matrix degrading enzymes in intrauterine infection and/or inflammation, only a few of such 
pregnancies (5-12% at term; and 20% preterm with PROM)(36) exhibit clinical signs of 
chorioamnionitis.(34) HCA is about 3 times more common than clinical chorioamnionitis, 
which is characterised by maternal fever, tachycardia, uterine tenderness, leucocytosis and 
preterm rupture of membranes (PROM);(31) and diagnosed by positive amniotic fluid culture 
of bacteria such as genital mycoplasmas.(37) Intrauterine infection may also occur through 
haematogenous spread, by invasive medical procedures, or by retrograde passage from the 
peritoneal cavity through the fallopian tubes, but most commonly by ascent from the vagina 
associated with a dysbiotic microbiota.(34, 37) 
 
Immune Profile 
The placental microenvironment in healthy pregnancies is biased toward a T-helper (Th)2 
(predominantly anti-inflammatory e.g. IL-4 and IL-10) cytokine milieu,(38) and reversal to 
Th1 cytokine (e.g. TNF-Į,)1-Ȗ,/-2 and IL-ȕGRPLQDQFHLVDVVRFLDWHGZLWKODERXU(39) 
The balance between Th1 (cell mediated and pro-inflammatory) and Th2 cytokines is 
considered a measure of the immune environment.(40) Alteration in this cytokine balance can 
lead to a breakdown of the maternal-fetal tolerance and rejection of the semi-allogenic 
fetus.(41) Increased expression of pro-inflammatory cytokines in the placenta, cord blood, 
maternal blood and cervicovaginal fluid is associated with poor pregnancy outcomes 
including placental dysfunction, intrauterine growth restriction (IUGR), preeclampsia and 
PTB.(38, 40, 42, 43) Placentas from women with PPROM and PTB indicate a bias towards 
Th1 cytokines IFN-Ȗ,/-2 and IL-12 compared to term placentas that show higher IL-4 and 
IL-10 (Th2) levels.(39) Elevated levels of IL-6 (produced by Th2 cells) and IL-8 (a 
chemokine produced by macrophages and monocytes) are also observed in preterm compared 
to term placentas. IL-6 is a highly sensitive and specific indicator of infection-induced PTL, 
while up to a 1000-fold increase in IL-8 expression have been observed in PTL with evidence 
of chorioamnionitis.(39) 
Choriodecidual colonisation by bacteria with release of pathogen associated molecular 
patterns (PAMPs, endo- and exotoxins) activate pattern recognition receptors (PRRs) such as 
toll-like receptors (TLRs) and nod-like receptors (NLRs) that are expressed by amnion 
epithelial cells, intermediate trophoblasts in the chorion, decidual cells, macrophages, and 
neutrophils.(44) These PRRs activate the pleiotropic transcription factor nuclear factor-ț%
(NF-ț% VLJQDO WUDQVGXFWLRQSDWKZD\1)-ț% UHJXODWHV the expression of pro-inflammatory 
cytokines, chemokines and antimicrobial peptides (e.g. defensins).(34, 37, 45) HCA in the 
setting of PTB is associated with significantly increased chorionic expression of TLR-1 and -
2 compared to PTB without HCA.(35) Regardless of membrane status (intact or ruptured) 
and gestational age (term or preterm), HCA is associated with increased expression of TLR-2 
and TLR-4 on chorioamniotic membranes.(45) TLR-2 recognizes microbial products of 
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gram-positive bacteria (peptidoglycan, lipoteichoic acid), genital mycoplasmas, and fungi; 
while TLR-4 recognizes bacterial endotoxin (Lipopolysaccharide, LPS).(45) TLR-4 
signalling pathway activates NF-ț% through the recruitment of adapter proteins (MyD88, 
IRAK1/4 and TRAF6) and activation of intermediate kinases (RIP1, TAB2/3, TAK1 and 
,..Įȕ (Fig. 1).(34) Other signalling pathways (p38MAP kinase/CREB) and modulators 
(histone deacetylase) that interact unselectively with NF-ț% signalling are also involved.(34, 
46) Key regulators of allogenic tolerance are decidual macrophages, specifically of the M2 
anti-inflammatory phenotype, and regulatory T cells (Tregs), which exhibit 
immunosuppressive properties. The placenta is capable of inducing these homeostatic 
macrophages and regulatory T cells to establish and maintain pregnancy with accumulation 
of Tregs having been observed in the decidua.(47)  
 
Cytokine Profile 
The downstream effect of NF-ț% DFWLYDWLRQ LV WKH UHOHDVH RI pro-inflammatory 
chemocytokines, which induce neutrophil activity, synthesis and release of PG, contractile 
associated proteins, and matrix metalloproteinases (MMPs) in the placental tissues and fetal 
membranes. The ultimate effect is increased myometrial contractility, cervical remodelling, 
membrane rupture, and PTB (Fig. 1).(37, 46), which can occur due to premature or 
pathological activation of NF-ț%(48)   
On the other hand, IL-10 inhibits the activity of NF-ț%,(49) and downregulates Th1-
associated cytokines and PGE2 expression.(50) IL-10 expression is stimulated by bacterial 
colonisation of the fetal membranes and amniotic cavity; and inflammation-associated 
intracellular signalling pathways e.g. MyD88, p38MAP kinase, CREB, and STAT.(46) 
Levels of IL-10 and IL-4 are elevated in placentas of women who delivered at term,(51) 
while placental IL-10 expression is reduced in pregnancies complicated by chorioamnionitis 
and PTL.(52) Similarly, low levels of IL-10 have been observed in umbilical cord blood of 
preterm neonates. However, high plasma levels of IL-10 have been reported in women who 
experienced PTB.(53) 
Another anti-inflammatory cytokine, transforming growth factor-ȕ 7*)-ȕ LV DOVR
secreted by the placenta.(51) Low cord blood levels of TGF-ȕEXWHOHYDWHG,/-10 have been 
found in women with placental inflammation.(54) High levels of TGF-ȕand IL-4 in maternal 
plasma have also been associated with high risk of PTB <35 weeks with HCA.(40) In a 
recent case-control study, low serum levels of IL-10 or TGF-ȕ RU ERWK VLPXOWDQHRXVO\
between 22-25 ZHHNV¶ gestation were associated with high risk of PTB independent of the 
presence of bacterial vaginosis (BV)(55). These regulatory cytokines(55) prevent 
inflammation-mediated damage to the fetus.(51) 
Another endogenous protein associated with immune reactivity and homeostasis in pregnancy 
is anti-secretory factor (AF). AF is present in the placenta and other human tissues and body 
fluid. It is also expressed by macrophages and dendritic cells with potent anti-inflammatory 
effects. It usually exists in an inactive form and becomes activated in response to exposure to 
bacterial toxins as part of the innate immune response. Placenta levels of active AF are 
inversely related to inflammation and decrease in PTB. It has been suggested that AF 
regulates placental inflammation during gestation by converting complement factor 3 to its 
inactive form and stimulating the activity of proteasomes. (56) 
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Bacterial colonisation of the placenta in the latter half of pregnancy elicits the so-called fetal 
inflammatory response syndrome (FIRS), through the stimulation of the fetal hypothalamic 
pituitary axis and the production of corticotropin-releasing hormone (CRH) from the 
placenta. Subsequently, there is increased fetal cortisol biosynthesis and decreased maternal 
cortisol metabolism. Cortisol stimulates PG synthesis and through a positive feedback loop 
induces placental CRH production. PG production is enhanced by concomitant 
downregulation of prostaglandin dehydrogenase (PGDH) within the chorion and the 
production of PTGS-2. Both CRH and PGs stimulate MMP production and infiltration of 
inflammatory mediators (37, 44). 
 
Sterile inflammation 
Some women with signs of intra-amniotic inflammation e.g. elevated amniotic fluid 
cytokines do not demonstrate clinical intra-amniotic infection.(33) For instance, in the 
absence of positive amniotic fluid bacterial cultures, elevated amniotic fluid IL-6, IL-Į,/-
ȕ OHYHOV have been shown to correlate with PTB before 34 weeks.(57) Elevated placental 
(58, 59) and cervical (50) cytokine levels have been described in women who delivered 
preterm without histologically confirmed intrauterine infection. Spontaneous PTB without 
infection is more common than PTL associated with infection. (60) (46) However, some 
pregnancies without microbial invasion of the amniotic cavity   but with bacteria localised to 
WKH IHWDO PHPEUDQHV PD\ EH PLVFODVVLILHG DV µVWHULOH¶ More so, because antibiotics are 
generally ineffective in preventing PTL and birth in women with infection, such PTBs may 
be the result of inflammation rather than infection.(34) Amongst other factors, the degree of 
immune response mounted by the host against the infectious agent is crucial to the ultimate 
reproductive outcome. This is because a significant proportion of women with inflammation 
of the gestational tissues who deliver prematurely do not have infection.(46, 61) Hence, for 
more effective prevention/treatment of PTB, co-administration of antibiotics and anti-
inflammatory agents has been recommended.(34) 
Sterile inflammation may be induced by cellular stress, tissue damage, and danger signals and 
is mediated by damage-associated molecular patterns (DAMPs) or alarmins, which activate 
PRRs. The non-microbial molecular drivers of sterile inflammation are usually associated 
with cell damage or death and are either intracellular ± high-mobility group box 1 (HMGB1), 
cell-free DNA, uric acid, heat shock proteins (e.g. Hsp70), IL-Į and mitochondrial 
components (DNA, ATP, N-formulated peptides); or extracellular ± extracellular matrix 
proteins (fibronectin, hyaluronan), oxidised phospholipids, fatty acids, advanced 
glycosylation end-products (AGEs), lipid oxidation products and oxysterols. These alarmins 
are released by the placenta and fetal membranes and provoke inflammation by activating 
PRRs on gestational tissues resulting in activation of NF-ț%DQGS0$3NLQDVHVLJQDOOLQJ
pathways which stimulate transcription of inflammatory genes. The ultimate outcomes 
include placental dysfunction, IUGR, preeclampsia and PTB (Fig 1).(42, 46) A detailed 
review of the role of cytokines in PTL is provided by Farina and Winkelman.(50) 
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Figure 1. Microbial and sterile inflammatory signalling pathways associated with preterm 
labour and birth. Both pathogen (PAMPs) and damage (DAMPs) associated molecular 
patterns activate NF-ț%E\LQWHUDFWLQJZLWKSDWWHUQUHFRJQLWLRQUHFHSWRUV7/5DQG1/5RQ
immune cells and gestational tissues. The pleiotropic NF-ț%UHJXODWHVWKHH[SUHVVLRQRISUR-
inflammatory mediators that activate the tripartite common pathway of labour and if before 
37 completed weeks of gestation, preterm birth (PTB).  
cffDNA: cell-free fetal DNA, CCL2: chemokine (C-C motif) ligand, DAMP: damage-associated molecular patterns, GCSF: 
granulocyte colony-stimulating factor, HMGB1: high-mobility group box 1, Hsp70: heat shock protein 70, IFN-Ȗ: 
interferon-gamma, ,..Įȕ: inhibitor of nuclear factor kappa B kinase subunit alpha/beta, ,ț%: inhibitor of nuclear factor of 
kappa B, IL-Į interleukin-1alpha, IL-ȕ: interleukin-1-beta, IL-6: interleukin-6, IL-8: interleukin-8, IRAK1/4: 
Interleukin-1 receptor-associated kinase ¼, LPS: lipopolysaccharide, LTA: lipoteichoic acids, MMP: matrix 
metalloproteinases, MSU: monosodium urate, mtDNA: mitochondrial DNA, MyD88: myeloid differentiation primary 
response 88, NF-ț%nuclear factor kappa B, NLR: nod-like receptor, PAMP: pathogen associated molecular patterns, PG: 
prostaglandins, PGN: peptidoglycans, PTB: preterm birth, RIP1: receptor interacting protein 1,  TAB2/3: transforming 
growth factor beta-activated kinase 1-binding protein 2/3, TAK1: transforming growth factor beta-activated kinase 1, TLR: 
toll-like receptor, TRAF6: tumour necrosis factor receptor associated factor.    
 
Chronic versus acute placental inflammation 
Placental infections affect different histologic components of this complex organ and are 
termed chorioamnionitis, intervillositis, villitis and deciduitis. Depending on the pathologic 
features expressed, placentitis could be acute or chronic. Both acute and chronic infectious 
villitis result from direct haematogenous spread of pathogens to the placenta, though whether 
the inflammatory cell types are neutrophils or macrophages and lymphocytes defines an acute 
or chronic villitis respectively (29, 62). Where cultures, PCR or additional methods fail to 
demonstrate an infection, a diagnosis of villitis of unknown aetiology (VUE) is made, a 
condition speculated to be related to dysregulation of the maternal immune system (63). The 
prevalence of VUE varies between studies with a range identified between 2% and 33.8% of 
all placentas having a positive diagnosis; it has been suggested that differences in diagnostic 
8 
 
criteria and sampling protocols may account for this broad range. VUE is mainly associated 
with term placentas and is often regarded as being a benign placental inflammatory lesion 
despite the more severe grades being associated with adverse neonatal outcomes (29, 63). 
 
An infiltration of neutrophils characterises acute infections, either chorioamnionitis or villitis, 
whereas the hallmark of chronic chorioamnionitis (CCA) is an infiltration of lymphocytes to 
the chorionic plate and chorionic membranes. Acute chorioamnionitis presents with a 
thickened amniotic membrane which can be easily separated from the amnion due to 
adhesions between the layers (62, 64), a feature which distinguishes it from the rarely 
observed condition, chronic chorioamnionitis (62, 64). VUE is diagnosed where there is no 
evidence to support an infectious aetiology and an infiltration of Hofbauer cells (fetal 
macrophages) and maternal T-lymphocytes are demonstrated with histologic staining 
techniques. Uniquely, the inflammatory processes in VUE involves immune cells from two 
different hosts and shows maternal cells damaging fetal tissue and a response resembling 
allograft rejection (29, 63, 65). 
 
Due to the controversy of terminologies used in describing placental lesions and diagnostic 
criteria, a group consensus has been developed to reduce definition and sampling differences 
between laboratories and to standardise grading and staging of inflammation, as detailed in 
Table 1.(30) 
 
Table 1. Amsterdam placental workshop group consensus on staging and grading of maternal 
and fetal inflammatory responses. 
  
Inflammatory Response 
 
Maternal Fetal 
Stage 
1 Early Acute subchorionitis or chorionitis Chorionic vasculitis or umbilical phlebitis 
2 Intermediate Acute chorioamnionitis 
Umbilical vasculitis (one or both 
arteries with or without vein) or 
umbilical panvasculitis (all three 
vessels) 
3 Advanced Necrotising chorioamnionitis Necrotising funisitis or concentric 
umbilical perivasculitis 
Grade 
1 Mild-Moderate No specific terminology/not severe No specific terminology/not severe 
2 Severe Acute chorioamnionitis, 
subchorionic abscesses 
Intense chorionic/umbilical 
vasculitis 
Other Chronic or subacute 
chorioamnionitis  
Associated fetal thrombi 
Peripheral funisitis  
Acute villitis  
Acute intervillositis with 
intervillous abscesses 
Decidual plasma cells 
Adapted from: Redline et al.,(66) and Khong et al.(30) 
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Acute inflammatory response to ascending infection is more common than chronic 
inflammatory lesions during gestation. Acute inflammatory response is characterised 
clinically and pathologically as feto-maternal neutrophilic infiltrates (Table 2). Neutrophilic 
migration to the chorioamnion is induced by elevated concentrations of intra-amniotic 
neutrophil chemokines such as IL-8.(29) Increase in histologic severity in both maternal and 
fetal acute inflammatory response usually correlates with time of onset of ascending infection 
during gestation. Usually maternal response precedes the fetal response.(67) 
On the other hand, the less well understood chronic inflammatory response could be focal or 
multifocal but without obvious relationship between aetiology or clinical outcome and 
severity of inflammation. Due to the expansive collection of placental locations at which 
chronic inflammatory cells can be observed, characterising chronic inflammatory lesions is 
often challenging. Chronic chorioamnionitis features in about 39% and 34% of cases of 
PPROM and PTB respectively.(29) It is especially common in late PTB which constitute up 
to 70% of premature deliveries. Additionally, chronic chorioamnionitis and elevated intra-
amniotic CXCL10 (T-cell chemokine) have been demonstrated in up to 60% of cases of fetal 
death suggesting a role of maternal anti-fetal rejection in certain cases of idiopathic fetal 
death.(29) Where chronic chorioamnionitis is observed histologically, a concomitant chronic 
deciduitis or VUE is commonly diagnosed. Similarly to VUE, chronic chorioamnionitis is 
regarded as being immunological in origin, though it is associated mainly with preterm births 
rather than term deliveries.(64)   
Chronic inflammatory response is characterised by incidental microscopic identification of 
chronic inflammatory cells including lymphocytes, plasma cells, histiocytes (tissue 
macrophages) and eosinophilic infiltrates, most commonly observed in the choriodecidual 
border of the chorion laeve (Table 3).(64) The degree and severity of T-lymphocyte 
infiltration is usually not up to the neutrophilic infiltration observed in acute 
chorioamnionitis. A ratio of neutrophil to lymphocyte shows useful predictive accuracy for 
PIR with 71.4% sensitivity, 77.9% specificity, 80.7% positive predictive value, and 67.8% 
negative predictive value.(24) 
It is proposed that the migration of CXCR3+ T cells from the maternal (decidua) to fetal 
tissue (chorioamniotic membranes) (amniotropism) is induced by high concentration of 
amniotic fluid CXCL10 and overexpression of CXCL9, -10, and -11 in the chorioamnion 
(Fig 2).(29) This is supported by the observation of elevated amniotic fluid CXCR3 and its 
ligands CXCL9 and -10 in women who experience PTL and PTB, and lesions of maternal 
anti-fetal rejection (e.g. chronic chorioamnionitis, chronic histiocytic intervillositis, villitis of 
unknown aetiology (VUE) and chronic deciduitis with plasma cells) compared to those 
without such lesions even though they deliver preterm. CXCR3, CXCL9 and CXCL10 are 
also higher in women with sPTL and PTB compared to those with labour at term. In addition, 
irrespective of the presence or absence of placental lesions, elevated CXCR3 is associated 
with PTL compared with labour at term. Interaction of CXCR3 and its IFN-Ȗ-inducible 
ligands (CXCL9, -10, and -11) stimulates migration of maternal CD8+ cytotoxic T-cells from 
peripheral circulation to the decidua and chorioamnion, increase production of Th1 and 
reduce synthesis of Th2 cytokines (Fig. 2). However, this phenotype is not observed in 
physiologic labour at term.(68) The blockage of CXCR3 could attenuate the chronic 
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inflammatory response associated with PTL and this could be beneficial in preventing 
maternal anti-fetal rejection and prematurity.  
Loss of allogenic tolerance is another potential mechanism for PTB. This occurs via an 
imbalance in Tregs, inflammatory Th17 cells and/or decidual macrophages. Tregs are essential 
for controlling excessive immune responses and tolerance and are influenced by resident 
microbiota in tissues other than the placenta, such as the gut, oral mucosa and the vagina. 
Induction and maintenance of Tregs relies on the local microbiota and changes to the 
Tregs/Th17 balance or microbial dysbiosis are linked to infections, increased neutrophil 
infiltration and a breakdown in commensal tolerance in mucosa. It is therefore not unrealistic 
for the placenta to exhibit a similar response whereby dysbiotic microbiota results in maternal 
anti-fetal rejection. (47, 69) 
Chronic chorioamnionitis, chronic histiocytic intervillositis, VUE and chronic deciduitis each 
present individual inflammatory features, however, they are rarely observed in isolation. 
Most commonly two or more of these conditions are seen and are termed overlap chronic 
placental inflammation (oCPI), which presents with unique inflammatory features separate to 
those noted individually.  
There is also the hypothesis that overlap chronic placental inflammation (oCPI) i.e. the 
presence of chronic chorioamnionitis, chronic histiocytic intervillositis, VUE and chronic 
deciduitis together in a tissue, could show unique inflammatory features compared to those 
seen in the rare cases when these conditions occur individually. For example, oCPI may 
represent an IgA-mediated immunological response characterised by elevated expression of 
CXCL13,(70) which is selectively chemotactic for B cells through its interaction with 
CXCR5.(71, 72) This hypothesis is derived from the inclusion of IgA positive plasma cells 
by oCPI-associated chronic deciduitis compared to isolated chronic deciduitis.(70) 
The eosinophils contribute to the fetal inflammatory infiltrate in both acute chronic vasculitis 
and eosinophilic/T-cell chronic vasculitis (ETCV) (Table 3).(67) Many cases of idiopathic 
chronic placental inflammation e.g. chronic chorioamnionitis or VUE are reflective of fetal 
allograft rejection characterised by infiltration of maternal cytotoxic lymphocytes (CD8+ T 
cells) and presence of fetal human leukocyte antigen (HLA)-specific antibodies in maternal 
serum.(29, 56)  
Furthermore, amniotic fluid concentration of glycodelin-A, which is associated with the 
maintenance of maternal tolerance against the semi-allogenic placenta/fetus is decreased in 
chronic chorioamnionitis. This is in addition to 31 differentially expressed proteins in cases 
of chronic chorioamnionitis compared to cases of acute chorioamnionitis or controls without 
inflammatory lesions.(29)  
The clinical presentation of PTB (especially <34 ZHHNV¶ gestation) is associated with 
placental pathologic features (Fig. 3). Ascending intrauterine infection/amniotic fluid 
infection has been shown to be associated with maternal vascular malperfusion (MVM) and 
common in cases of PPROM. Women with preeclampsia show changes associated with 
severe MVM. Irrespective of the presence of intrauterine/amniotic infection, lymphocyte 
inflammation (chronic chorioamnionitis and VUE) was identified in all clinical presentations 
of PTB implicating maternal anti-fetal immunologic rejection. Chronic chorioamnionitis and 
basal villitis are also associated with cases of placental abruption showing laminar decidual 
necrosis and acute retroplacental haemorrhage.(73) 
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Table 2. Characteristics of acute placental inflammatory responses (Amsterdam criteria(30))  
 
 
Table 3. Characteristics of chronic placental inflammatory responses (Amsterdam 
criteria(30)) 
Chronic inflammatory response Cellular  infiltration 
Chronic deciduitis 
Lymphocytes (CD8+ T-cells) 
Plasma cells 
Histiocytes 
Eosinophils 
Basal chronic villitis 
Chronic villitis 
Chronic intervillositis 
Chronic chorioamnionitis 
Eosinophilic/T-cell chronic vasculitis 
Placental inflammatory response could be predicted by maternal serum neutrophil-
lymphocyte ratio.(24) 
 
 
Acute inflammatory response 
Maternal response Fetal response 
Acute deciduitis Acute umbilical phlebitis and/ or arteritis 
Acute subchorionitis Chorionic vasculitis  
Acute chorioamnionitis Acute chorionitis 
Acute severe/necrotizing chorioamnionitis Acute funisitis (Wharton¶V jelly) 
 
Neutrophilic infiltration 
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Figure 2. Disruption of maternal-fetal tolerance during pregnancy. Chronic inflammatory 
lesions of the placenta are associated with overexpression of CXCR3 (a transmembrane G-
protein coupled receptor) by the villous cytotrophoblasts and syncytiotrophoblasts, 
chorioamnion and decidua. Binding of CXCR3 to its IFN-Ȗ-inducible chemokine ligands 
(CXCL9, -10, and -11) generates a T-cell chemokine gradient from the amniotic fluid and 
increases CD8+ cytotoxic T cell infiltration of the decidua and fetal membranes. This 
stimulates cell- and antibody mediated immune responses that lead to chronic 
chorioamnionitis, villitis of unknown aetiology, and chronic deciduitis with plasma cells that 
are placental lesions associated with maternal anti-fetal rejection, fetal growth restriction and 
spontaneous preterm labour (sPTL).(29, 68) 
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A successful pregnancy largely depends on an optimal immune response to the fetal allograft 
and microbial and other stimuli.(20, 74-76) Interruption of the tolerogenic state associated 
with a healthy pregnancy results in maternal anti-fetal rejection, placental damage, and 
pregnancy complications including fetal growth restriction and spontaneous miscarriage or 
PTL (sPTL). This allograft rejection is either cellular (T-cell) or antibody (humoral) 
mediated; an extreme form of such rejection is fetal death similar to graft failure in organ 
transplantation(29). It is hypothesised that villitis of unknown aetiology (VUE), an under-
recognised yet significant diagnosis, which is discussed in more detail within this review, 
results in a distinct fetal systemic inflammatory response akin to allograft rejection or graft 
versus host disease (GvHD) despite the absence of identifiable pathogens (29, 63). 
 
Evidence in favour of a placental microbiome 
 
Detection of urogenital microbes in the uterus or bacterial colonisation of the placenta and/or 
amniotic membranes has traditionally been speculated to result in subclinical infection, such 
as chorioamnionitis, and a concomitant initiation of labour.(20, 77-79) Microbes ascending 
from the vagina, including group B Streptococcus, and Ureaplasma and Mycoplasma species, 
have been associated with chorioamnionitis, placental and membrane colonisation and PTB. 
Interestingly, non-urogenital bacterial species, such as Streptococcus and Fusobacterium 
spp., which are normally found in the oral cavity, have also been linked to placental and fetal 
colonisation and chorioamnionitis, further supporting the hypothesis of heamatogenous 
transfer of microbial organisms to contribute to a placental microbiome.(76, 80, 81) Placentas 
delivered by sterile Caesarean section following term pregnancy with an absence of infection 
were found to harbour bacteria, as did amniotic fluid from women who had intact 
membranes.(5) Doyle et al., (2017) used 16S ribosomal RNA gene sequencing to analyse 
placental and fetal membrane microbial communities in a rural Malawi cohort reported a 
placental microbiome at delivery distinct from the vaginal and oral microbiomes. An 
increased bacterial load of Fusobacterium nucleatum, Ureaplasma spp. and Gemella 
asaccharolytica was identified in the fetal membranes and this was shown to correlate with 
shorter gestation and PTB.(82) A placental microbiome resembling that of the oral cavity, 
specifically the tongue and tonsils, was identified in a study of 320 women. Whilst of a low 
abundance, bacteria of the species Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes, 
and Fusobacteria were found to be present in placentas following 16S rRNA sequencing (20) 
challenging previous constructs that the placenta has no microbiome.(20, 74-76) 
 
Evidence against a placental microbiome 
 
Conversely, many sequencing-based studies have failed to identify a placental microbiome 
(75, 83-86), suggesting instead that contamination by reagents used in 16S gene sequencing 
is the cause of microbial identification and reported placental microbiomes, a recognised 
vulnerability of sequencing studies, especially when studying tissue with a low bacterial 
abundance such as the placenta.(87) Alternative sources of contamination which may be 
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misinterpreted as suggesting a placental microbiome have been attributed to environmental 
sources, either during or after delivery or from maternal faeces.(20, 85-87) The lack of a 
placental microbiome has garnered further support following a DNA-sequencing approach 
study of villous tissue samples from 537 women including negative controls of samples free 
of biological material. This research found no evidence of a functional placental microbiome 
and demonstrated that bacterial DNA contamination was from laboratory reagents or 
acquisition during labour or delivery (75).  
 
Placental microbial metabolite profile 
By combining the application of 16S ribosomal DNA±based and whole-genome shotgun 
(WGS) metagenomic sequencing analyses with multiplex bead-based immunoassay, 
researchers have observed that changes in placental microbiota that influence delivery 
outcome are accompanied by variations in microbiota-induced metabolic pathways.(20, 74, 
76) These alterations appear not to be influenced by whether the placentas were delivered 
vaginally or through caesarean section.(20)  
The placentas of women who deliver at term without chorioamnionitis show significant 
positive correlation between Acinetobacter spp. and Streptococcus thermophilus, and 
functional pathways involving metabolism of cofactors and vitamins such as riboflavin, 
nicotinate and nicotinamide, vitamin B6, pentothenate and CoA. These pathways were 
similarly related to L. crispatus, Acinetobacter spp, Streptococcus spp., Fusobacterium spp. 
and Enterobacter spp. in preterm women without chorioamnionitis.(76) However, women 
with chorioamnionitis irrespective of birth outcome showed alterations in biosynthesis of 
secondary metabolites (e.g. phenylpropanoid, stilbenoid, diarylheptanoid and gingerol) and 
lipid (glycerolipid, glycerophospholipid, arachidonic acid and unsaturated fatty acids) 
metabolism associated with increased abundance of oral commensal bacteria - S. 
thermophilus and Fusobacterium spp. Furthermore, in the term women, those with 
chorioamnionitis had significantly lower butanoate and riboflavin metabolism compared to 
those without chorioamnionitis.  Butyrate from butanoate metabolism inhibits inflammation 
in the gut,(74) while decreased riboflavin metabolism is associated with inflammation. This 
altered secondary metabolite biosynthesis is most likely associated with the observed 
histologic inflammatory responses in term placentas with chorioamnionitis.(76)  
On the other hand, the preterm women with chorioamnionitis showed significantly increased 
pentose phosphate pathway (PPP), glycerophospholipid metabolism and biosynthesis of 
siderophores compared to those without chorioamnionitis. The increased PPP is considered to 
be related to the reduced amniotic fluid glucose observed in chorioamnionitis and PTB as 
glucose feeds into the PPP.(88) Glycerophospholipids are metabolised to arachidonic acid, 
which promotes inflammation and prostaglandin (PG) synthesis, both required for initiation 
of labour.(76) Siderophores are iron-chelating molecules released by aerobic and facultative 
anaerobic bacteria that require iron for proliferation.(89, 90) Some of such bacteria (e.g. 
Gardnerella vaginalis) have been associated with dysbiosis and adverse reproductive 
outcomes,(90) compared to lactic acid-producing Lactobacilli that do not require iron for 
growth and proliferation.(90) Increased siderophores in preterm placenta is also possibly 
related to iron deficiency anaemia. It may also be a causative factor that triggers PTB as 
response to aggravated iron status.(74) 
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Elevated amounts of folic acid has also been observed in the placenta of preterm women 
without excess gestational weight gain.(74) This observation is one of several mixed and 
contradictory reports present in the literature.(74) For instance, one study suggested that folic 
acid supplementation initiated beyond the first and second trimester is associated with 
increased risk of PTB but this was reported without accounting for confounding factors that 
may affect this association.(91) This observation conflicts with the slight reduction in PTB 
risk observed in other studies,(92), highlighting the need for further studies to confirm the 
role of folic acid supplementation before and/or during pregnancy.(91, 92) 
 
Conclusion and Future directions 
There is a growing emphasis on the potential significance of the placental microbiome and 
microbiome-metabolite interactions in immune responses and subsequent pregnancy 
outcome, especially in relation to preterm birth, however the existence of a placental 
microbiome remains open for debate. Whilst studies have shown the presence of commensal 
bacteria in the placenta, many others have found this to be due to contamination from the 
environment and/or gene sequencing reagents or methods. It has been suggested that poor 
pregnancy outcomes result from an inflammatory response originating from the mother, fetus 
and/or placenta. Dysbiosis of the vaginal, gut or placental microbiome and subsequent 
alterations to secondary metabolite biosynthesis are important in the development of 
infection, inflammation and pathogenesis of preterm labour. Aberrant placental, maternal and 
fetal inflammatory responses are implicated in premature activation of the pathways involved 
in labour. However, early determination of placental pathological pathways associated with 
PTB remains challenging. There is a dearth of functional placental experimental models 
necessitating further investigation to elucidate the role of the placenta in the molecular 
pathways involved in gestation-specific initiation of parturition. A comprehensive 
investigation involving the omics techniques including genomics, transcriptomics, 
proteomics, metabolomics and lipidomics across different races and ethnic groups is 
necessary to determine the phenotypes and functions of the placental microbiome and 
physicochemical signature and the consequent feto-maternal inflammatory (immune) 
reactions that may lead to maternal anti-fetal rejection and prematurity. Novel predictive 
markers of preterm birth may become available based on the understanding of the placHQWD¶V
contribution to the timing of delivery. 
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Figure 3. Association of clinical presentation of preterm birth and placental pathologic features. Lymphocytic inflammation manifests as chronic 
chorioamnionitis, villitis of unknown aetiology and chronic deciduitis related to preeclampsia and essential hypertension, all of which are 
placental inflammatory lesions observed in maternal fetal allograft rejection. Histologically, maternal vascular malperfusion (MVM) correlates 
with uterine ischemia.(73) FVM, fetal vascular malperfusion; IUGR, intrauterine growth restriction; PPROM, preterm premature rupture of 
membrane; SGA, small for gestational age; sPTL, spontaneous preterm labour.(93-95) 
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